том 55 издание 3 страницы 108-114

Synthesis of [14C]boceprevir, [13C3]boceprevir, and [D9]boceprevir, a hepatitis C virus protease inhibitor

Sumei Ren 1
Pernilla Royster 1
Carolee Lavey 1
David Hesk 1
Paul McNamara 1
David Koharski 1
Van Truong 1
Scott Borges 1
1
 
Merck Research Laboratories; 126 E. Lincoln Avenue, PO Box 2000; Rahway; NJ; 07065; USA
Тип публикацииJournal Article
Дата публикации2012-01-18
scimago Q3
wos Q4
БС2
SJR0.271
CiteScore2.0
Impact factor0.9
ISSN03624803, 10991344
Organic Chemistry
Drug Discovery
Biochemistry
Spectroscopy
Analytical Chemistry
Radiology, Nuclear Medicine and imaging
Краткое описание
Boceprevir is a hepatitis C virus (HCV) NS3 protease inhibitor for HCV treatment. [14C]Boceprevir (SCH 503034, trade name Victrelis) was synthesized from K14CN in 11 steps with an overall yield of 16.4%. [13C3]Boceprevir was synthesized in 16 steps with a 2.5% overall yield. The carbon-13 in the molecule was distributed along the peptide chain. [D9]Boceprevir was synthesized from [D9]-t-butylamine in four steps with an overall yield of 69%. Copyright © 2012 John Wiley & Sons, Ltd.
Найдено 
Найдено 

Топ-30

Журналы

1
2
Organic Letters
2 публикации, 66.67%
Russian Chemical Bulletin
1 публикация, 33.33%
1
2

Издатели

1
2
American Chemical Society (ACS)
2 публикации, 66.67%
Springer Nature
1 публикация, 33.33%
1
2
  • Мы не учитываем публикации, у которых нет DOI.
  • Статистика публикаций обновляется еженедельно.

Вы ученый?

Создайте профиль, чтобы получать персональные рекомендации коллег, конференций и новых статей.
Метрики
3
Поделиться
Цитировать
ГОСТ |
Цитировать
Ren S. et al. Synthesis of [14C]boceprevir, [13C3]boceprevir, and [D9]boceprevir, a hepatitis C virus protease inhibitor // Journal of Labelled Compounds and Radiopharmaceuticals. 2012. Vol. 55. No. 3. pp. 108-114.
ГОСТ со всеми авторами (до 50) Скопировать
Ren S., Royster P., Lavey C., Hesk D., McNamara P., Koharski D., Truong V., Borges S. Synthesis of [14C]boceprevir, [13C3]boceprevir, and [D9]boceprevir, a hepatitis C virus protease inhibitor // Journal of Labelled Compounds and Radiopharmaceuticals. 2012. Vol. 55. No. 3. pp. 108-114.
RIS |
Цитировать
TY - JOUR
DO - 10.1002/jlcr.1960
UR - https://doi.org/10.1002/jlcr.1960
TI - Synthesis of [14C]boceprevir, [13C3]boceprevir, and [D9]boceprevir, a hepatitis C virus protease inhibitor
T2 - Journal of Labelled Compounds and Radiopharmaceuticals
AU - Ren, Sumei
AU - Royster, Pernilla
AU - Lavey, Carolee
AU - Hesk, David
AU - McNamara, Paul
AU - Koharski, David
AU - Truong, Van
AU - Borges, Scott
PY - 2012
DA - 2012/01/18
PB - Wiley
SP - 108-114
IS - 3
VL - 55
SN - 0362-4803
SN - 1099-1344
ER -
BibTex |
Цитировать
BibTex (до 50 авторов) Скопировать
@article{2012_Ren,
author = {Sumei Ren and Pernilla Royster and Carolee Lavey and David Hesk and Paul McNamara and David Koharski and Van Truong and Scott Borges},
title = {Synthesis of [14C]boceprevir, [13C3]boceprevir, and [D9]boceprevir, a hepatitis C virus protease inhibitor},
journal = {Journal of Labelled Compounds and Radiopharmaceuticals},
year = {2012},
volume = {55},
publisher = {Wiley},
month = {jan},
url = {https://doi.org/10.1002/jlcr.1960},
number = {3},
pages = {108--114},
doi = {10.1002/jlcr.1960}
}
MLA
Цитировать
Ren, Sumei, et al. “Synthesis of [14C]boceprevir, [13C3]boceprevir, and [D9]boceprevir, a hepatitis C virus protease inhibitor.” Journal of Labelled Compounds and Radiopharmaceuticals, vol. 55, no. 3, Jan. 2012, pp. 108-114. https://doi.org/10.1002/jlcr.1960.